comparemela.com

Latest Breaking News On - Bharat biotechs covaxin - Page 2 : comparemela.com

20 crore doses given, 34% above 45 have got 1st jab | India News

Covaxin demonstrates protection against new Covid-19 variants

Covaxin demonstrates protection against new Covid-19 variants SECTIONS Last Updated: May 16, 2021, 01:25 PM IST Share Synopsis A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively. PTI Bharat Biotech s Covaxin retained neutralising activity against emerging variants of coronavirus, as per a new study. Peer-review publication, Clinical Infectious Diseases, has noted that Covaxin demonstrates protection against the new Covid-19 variants. Bharat Biotech s Covaxin retained neutralising activity against emerging variants of coronavirus, as per a new study. A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively.

Covid-19: Union health secy writes to states, UTs on phase 3 inoculation drive | India News

NEW DELHI: From May 1, the types of anti-coronavirus vaccine and their prices will be displayed on the CoWIN portal for citizens to make an informed choice at the time of booking an appointment at a private vaccination centre. While those aged 18 to 44 years will be eligible to receive vaccination on payment from any of the private Covid vaccination centres (CVCs), citizens below 45 years shall also be eligible to receive a jab from a government CVC in a state or Union Territory which decides to lower the minimum cut off age for eligibility. The registration of citizens in the 18-44 age group will start on the CoWIN portal from April 28.

Karnataka CM Yediyurappa discharged from hospital after recovering from COVID

Karnataka CM Yediyurappa discharged from hospital after recovering from COVID SECTIONS Last Updated: Apr 22, 2021, 12:24 PM IST Share Synopsis The 78-year old leader was hospitalised on April 16, after he tested positive for COVID-19 for the second time in eight months. PTI Karnataka Chief Minister B S Yediyurappa was on Thursday discharged from the private hospital here where he was undergoing treatment for COVID-19. He was discharged from the city s Manipal hospital, where he has been undergoing treatment for the last five days, his office said. The 78-year old leader was hospitalised on April 16, after he tested positive for COVID-19 for the second time in eight months.

Biological E jabs may hit market by August, says Dr VK Paul

Biological E jabs may hit market by August, says Dr VK Paul SECTIONS Last Updated: Apr 22, 2021, 08:04 AM IST Share Synopsis As per the ICMR , Biological E is testing a two-dose vaccine. Similar to Bharat Biotech’s Covaxin, Biological E’s vaccine under trial prescribes doses to be given at a 28-day gap. India is likely to get a fourth Covid-19 vaccine in August. Biological E, a Hyderabad-based biopharmaceutical company, has completed phase-1/2 human clinical trials and would submit the data soon. Following this, the company would initiate phase-3 trials for the indigenously developed vaccine. Niti Aayog member (health) Dr VK Paul said, “Biological E has finished phase-1/2 trials. They are submitting the data in the next few days after which they will initiate phase-3 trials. Biological E is into manufacturering of childhood vaccines.” Biological E is the largest manufacturer of tetanus vaccines and snake venom antidotes in India.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.